Premium
Antibody‐antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer
Author(s) -
Haisma Hidde J.,
Battaile Anne,
Stradtman Earl W.,
Knapp Robert C.,
Zurawski Vincent R.
Publication year - 1987
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910400608
Subject(s) - antibody , antigen , monoclonal antibody , ovarian cancer , ovarian carcinoma , immunotherapy , chemistry , medicine , immunology , microbiology and biotechnology , cancer , biology
Monoclonal antibody (MAb) OC125 binds to approximately 80% of epithelial ovarian cancers. Serum antigen, CA125, can be detected in these patients. 131 1‐OC125‐F(ab) 2 was injected into 5 ovarian carcinoma patients with preinjection serum levels of 150 to 9,000 CA125 U/ml. Patients received the antibody intravenously in doses ranging from 0.46 to 0.94 mg with a specific activity of approximately 2.5 mCi/mg 131 1. The half‐ life in the circulation was approximately 30 hr and was independent of serum CA125 levels. Clearance of 131 1 from the circulation fitted an open, one‐compartment mathematical model. Gel filtration chromatography revealed antibody‐antigen complexes in sera 15 min after injection of the radiola‐belled antibody. By 5 days after injection, the free form of OC 125 antibody could not be detected in the serum. The rate of complex formation correlated well with the observed preinjection serum CA125 levels. This direct correlation was verified in vitro using purified CA125 antigen and radiola‐beled OC125 F(ab) 2 fragments. The specific effects of complex formation on tumor localization remains unclear. However, the presence of complexes should not be ignored, when planning for diagnostic imaging or immunotherapy with OC 125 or other MAbs reacting with circulating antigen.